title: Presymptomatic thyroidectomy in multiple endocrine neoplasia 2a.
abstract: OBJECTIVE
  To evaluate the value of prophylactic total thyroidectomy in multiple endocrine neoplasia 2a (MEN 2a), based on results of genetic testing, in a presymptomatic early stage of the disease.
  
  
  METHODS
  Fourteen presymptomatic patients genetically diagnosed and surgically treated at our centre. We analysed age, gender, location of the RET mutation, calcitonin tests, surgery, histologic findings, TNM classification, and postoperative follow-up.
  
  
  RESULTS
  The 14 patients belonged to two families with MTC (MEN 2a). Median age was 16 years. The RET mutation was located in codon 618 and 634. Basal calcitonin (CT) levels were normal in all patients. Twelve had pathologic peak CT measurements. Total thyroidectomy was performed in all and associated central neck dissection in 12 patients. Pathohistologic assessment showed C-cell hyperplasia in all specimens and 11 MTCs; the median size of the tumours was 0.2 cm; two patient had lymph-node metastases. According to TNM, three had stage 0, nine had stage I, one had stage II, and one had stage III disease. Postsurgery basal and peak CT values were normal in all but one patients, indicating a biochemical curative rate of 95%. Calcitonin determination did not distinguish between MTC and C-cell hyperplasia.
  
  
  CONCLUSIONS
  Prophylactic thyroidectomy based on genetic testing allows identification and treatment of patients at an early stage of the disease. Pathologic peak CT values are markers for the presence of microscopic MTC and should be considered in selecting operative procedures for these patients.
authors.affiliation: Departement Chirurgie, Allgemeinchirurgische Klinik, Universitätsspital Basel, Spitalstrasse 21, CH-4031 Basel, Switzerland. oheizmann@uhbs.ch
authors.forename: O
authors.initials: O
authors.lastname: Heizmann
authors.forename: F-M
authors.initials: FM
authors.lastname: Haecker
authors.forename: U
authors.initials: U
authors.lastname: Zumsteg
authors.forename: B
authors.initials: B
authors.lastname: Müller
authors.forename: M
authors.initials: M
authors.lastname: Oberholzer
authors.forename: D
authors.initials: D
authors.lastname: Oertli
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood; D002116:Calcitonin / Q000097:blood; D018276:Carcinoma, Medullary / Q000097:blood / Q000473:pathology / Q000601:surgery*; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D018813:Multiple Endocrine Neoplasia Type 2a / Q000097:blood / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013964:Thyroid Neoplasms / Q000097:blood / Q000473:pathology / Q000601:surgery*; D013965:Thyroidectomy / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D002116:Calcitonin